Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-Thiazolylquinazolines

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 4, 2003, Pages 637-640

  Gaul, Micheal D ^a,b   Guo, Yu ^a   Affleck, Karen ^a   Cockerill, G Stuart ^a,c   Gilmer, Tona M ^a   Griffin, Robert J ^a   Guntrip, Stephen ^a   Keith, Barry R ^a   Knight, Wilson B ^a   Mullin, Robert J ^a   Murray, Doris M ^a   Rusnak, David W ^a   Smith, Kathryn ^a   Tadepalli, Sarva ^a   Wood, Edgar R ^a   Lackey, Karen ^a  

^a GLAXOSMITHKLINE   (United States)

^b JOHNSON AND JOHNSON   (United States)

^c Arrow Therapeutics   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; LAPATINIB; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; ONCOGENE NEU; STRUCTURE ACTIVITY RELATION;

ANIMALIA;

EID: 0037294422     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)01047-8     Document Type: Article

References (13)

1. Slichenmeyer W.J., Elliott W.L., Fry D.W. Semin. Oncol. 28(Suppl. 16):2001;67.
2. Rowinsky E.K. Horizons in Cancer Therapeutics: From Bench to Bedside. 2:2001;2.
3. Cockerill S.G., Lackey K.E. Curr. Topics Med. Chem. 2:2002;1001.
4. Adams J.A. Chem. Rev. 101:2001;2271.
5. Yarden Y., Sliwkowski M.X. Nat. Rev. 2:2001;127.
6. Dumas J. Curr. Opin. Drug Discov. Develop. 4:2001;378.
7. Bridges A.J. Chem. Rev. 101:2001;2541.
8. Hudson, A. T.; Vile, S.; Barraclough, P.; Franzmann, K.W.; McKeown, S. C.; Page, M. J. WO 9609294 A1, 1996.
9. Schwarz, G. Org. Synth. Coll., 1955; Vol. III, p 332.
10. Affleck, K.; Allen, P.; Alligood, K. J.; Cai, Z.; Carter, M. C.; Cockerill, G. S.; Crosby, R. M.; Dickerson, S.; Frye, S. V.; Gaul, M.; Gauthier, C.; Gilmer, T. M.; Glennon, K.; Griffin, R.; Guntrip, S. B.; Guo, Y.; Johnson, N. W.; Keith, B. R.; Knight, W. B.; Luzzio, M.; Mook, R. A.; Mullin, R. J.; Murray, D. M.; Rusnak, D. W.; Tadepalli, S. M.; Sinhababu, A. K.; Smith, K. J.; Wood, E.; Zhang, Y.; Lackey, K. In Proc. Am. Assoc. Cancer Res. 92nd Annual Meeting, New Orleans, LA, 2001.
11. Brignola P.S., Lackey K., Kadwell S.H., Hoffman C., Horne E., Carter H.L., Stuart J.D., Blackburn K., Moyer M.B., Alligood K.J., Knight W.B., Wood E.R. J. Biol. Chem. 277:2002;1576.
12. 2/2. Compounds were administered po using a 10% sulfobutyl ether beta cyclodextrin formulation. These studies were performed under under a protocol approved by the institutional animal care committee.
13. Rusnak D.W., Lackey K., Affleck K., Wood E.R., Alligood K.J., Rhodes N., Keith B., Murray D.M., Mullin R.J., Knight W.B., Gilmer T.M. Mol. Cancer Thera. 1:2001;85.